News

Inhibiting an enzyme called USP13 may represent an attractive therapeutic target for Parkinson’s and other neurodegenerative diseases, preclinical data suggests. These findings also could hold important implications for a therapy currently being developed to treat Parkinson’s disease — nilotinib. The study, “Ubiquitin specific protease-13 independently regulates parkin…

An investigational vaccine being developed by United Neuroscience (UNS) presented several advantages over traditional vaccines to treat progressive disorders, such as Parkinson’s disease, according to preclinical data. The vaccine, called UB-312, was more selective to prevent toxic aggregates of alpha-synuclein in mouse models of the disease. These latest findings were…

Results from preclinical studies show the PIG3 protein as a key player in LRRK2-mediated familial Parkinson’s disease. The findings were discussed in two presentations at the Society for Neuroscience (SfN) 2018 annual meeting in San Diego, California. Mutations in the LRRK2 gene — the leading genetic cause of Parkinson’s — account for…